The treatment landscape for de novo metastatic hormone sensitive prostate cancer (mHSPC) is rapidly evolving. With an abundance of available treatment strategies, selecting the optimal strategy for an individual patient is becoming increasingly challenging. TripleAiM1 aims to evaluate the impact of mHSPC treatments on health-related quality of life (HRQoL) and to provide real-world data insights on diagnostics, treatment strategies, patient subgroups and related healthcare expenditure for mHSPC. The aspirational target of TripleAiM1 is that in the near future, a more tailored therapy can be offered based on the individual patient's wishes and needs in accordance with the overarching principle of value-based healthcare.
We describe the TripleAiM1 study design; a nationwide registry comprising a retrospective and prospective cohort of patients with de novo mHSPC. Starting in May 2020, eligible patients are identified, selected and recruited in 14 participating hospitals in the Netherlands. Our hypothesis is that, in a real-world setting, differences in clinically meaningful HRQoL deterioration will be observed for treatment strategies over time. HRQoL data, assessed with patient-reported outcome measures, costs and clinical data will be collected for 24 months.For the retrospective cohort, all patients diagnosed with de novo mHSPC from January 2017 onwards are eligible for inclusion. Patient and tumour characteristics, imaging modalities and treatment patterns will be analysed descriptively to provide a real-world overview.Time-to-event endpoints will be assessed using the Kaplan-Meier method and regression models will be employed to analyse baseline characteristics associated with an increased likelihood of death, progression and HRQoL deterioration. Longitudinal mixed-effects models will be employed to assess change of patient-reported outcome scores from baseline until the end of follow-up.
Ethical approval was obtained from the Medical Research Ethics Committee, Twente. Study results will be published in peer-reviewed journals.
NL9719.
BMJ open. 2023 Aug 29*** epublish ***
Tessa van Elst, Jean-Paul van Basten, Pieter van den Berg, Roderick van den Bergh, Sjaak Bloem, Joyce van Dodewaard-de Jong, Mathijs Hendriks, Sjoerd Klaver, Zarina Lalmahomed, Daphne Luijendijk, Addy van de Luijtgaarden, Luc Roelofs, André Vis, Gerard Vreugdenhil, Eric Vrijhof, Bart Wijsman, Haiko Bloemendal, Peter Mulders, Niven Mehra
Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands ., Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Medical Oncology, Tergooi MC, Hilversum, The Netherlands., Urology, St Antonius Hospital, Utrecht, The Netherlands., Nyenrode Business Universiteit Expertise Center Marketing and Supply Chain Management, Breukelen, The Netherlands., Medical Oncology, Meander MC, Amersfoort, The Netherlands., Medical Oncology, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands., Urology, Maasstad Ziekenhuis, Rotterdam, The Netherlands., Janssen Cilag BV, Tilburg, The Netherlands., Urology, Martini Hospital, Groningen, The Netherlands., Medical Oncology, Reinier de Graaf Gasthuis, Delft, The Netherlands., Urology, Treant Care Group Hospital, Emmen, The Netherlands., Urology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands., Medical Oncology, Maxima Medical Centre, Veldhoven, The Netherlands., Urology, Catharina Hospital, Eindhoven, The Netherlands., Urology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, The Netherlands., Medical Oncology, Radboudumc, Nijmegen, The Netherlands., Urology, Radboudumc, Nijmegen, The Netherlands.